Chinese Academy of Medical Sciences

Hebei Medfaith Pharmaceutical Technology Co., Ltd.

Juxian Wang

Yucheng Wang

Mei Zhu

Minghua Wang

Xiaonan Du

Xingang Wang

Hongwei He

Shuangshuang Zhao

Maoxu Ge

Rongguang Shao

Jinfeng Ren

Naren Li

Xuefu You

Hongwei Tian

Shi-Ying Cai

Guoning Zhang

The present disclosure is related to the field of enzyme inhibitors, and in particular to a hydroxamic acid derivative, a method for producing the same and use thereof. The hydroxamic acid group of the hydroxamic acid derivative can be chelated with zinc ions in the LpxC active area, and the derivative has a hydrophobic side chain which can bind to hydrophic channels in the enzyme LpxC. These guarantee that the hydroxamic acid derivative has good bactericidal activity against Gram-negative bacteria and low toxicity. The present disclosure also provides a method for producing the hydroxamic acid derivative, which requires a shorter reaction time and can provide the derivative with a high yield.

Hydroxamic acid derivative, method for producing same and use thereof

The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.

Use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis

Growing community of inventors

Beijing, China

Juxian Wang